<unk>  is a HMG-CoA Reductase Inhibitor that is FDA approved for the {{{indicationType}}} of reductions in risk of CHD mortality and cardiovascular events, hyperlipidemia, adolescent patients with heterozygous familial hypercholesterolemia (HeFH).   Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection.
Simvastatin
Ezetimibe
Mevastatin
Cholestyramine
Fluvastatin
Lovastatin
Clofibrate
Atorvastatin